These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 11010835

  • 1. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guérin as therapy for superficial bladder cancer: a comparative study.
    de Boer EC, De Reijke TM, Vos PC, Kurth KH, Schamhart DH.
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S109-14. PubMed ID: 11010835
    [Abstract] [Full Text] [Related]

  • 2. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin) for superficial bladder cancer immunotherapy--a phase I/II study.
    de Reijke TM, de Boer EC, Schamhart DH, Kurth KH.
    Urol Res; 1997 Sep; 25(2):117-20. PubMed ID: 9144878
    [Abstract] [Full Text] [Related]

  • 3. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM, de Boer EC, Kurth KH, Schamhart DH.
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [Abstract] [Full Text] [Related]

  • 4. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE.
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [Abstract] [Full Text] [Related]

  • 5. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
    De Boer EC, Rooijakkers SJ, Schamhart DH, Kurth KH.
    J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
    [Abstract] [Full Text] [Related]

  • 6. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T.
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [Abstract] [Full Text] [Related]

  • 7. Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin.
    De Boer EC, De Jong WH, Steerenberg PA, Van der Meijden AP, Aarden LA, Debruyne FM, Ruitenberg EJ.
    In Vivo; 1991 Feb; 5(6):671-7. PubMed ID: 1810454
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression.
    Thalmann GN, Dewald B, Baggiolini M, Studer UE.
    J Urol; 1997 Oct; 158(4):1340-4. PubMed ID: 9302115
    [Abstract] [Full Text] [Related]

  • 9. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
    Kaczmarek P, Błaszczyk J, Fijałkowski P, Sierakowska-Fijałek A, Niemirowicz J, Kasprzak A, Baj Z.
    Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer.
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK.
    J Urol; 2002 Jan; 167(1):364-7. PubMed ID: 11743357
    [Abstract] [Full Text] [Related]

  • 11. Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas.
    Elsässer-Beile U, Gutzeit O, Bauer S, Katzenwadel A, Schultze-Seemann W, Wetterauer U.
    J Urol; 2000 Jan; 163(1):296-9. PubMed ID: 10604379
    [Abstract] [Full Text] [Related]

  • 12. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
    Sanchez-Carbayo M, Urrutia M, Romani R, Herrero M, Gonzalez de Buitrago JM, Navajo JA.
    Anticancer Res; 2001 Jan; 21(4B):3041-7. PubMed ID: 11712808
    [Abstract] [Full Text] [Related]

  • 13. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M.
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [Abstract] [Full Text] [Related]

  • 14. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J.
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [Abstract] [Full Text] [Related]

  • 15. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L, Cesson V, Lucca I, Cerantola Y, Valerio M, Fritschi U, Vlamopoulos Y, Burruni R, Legris AS, Dartiguenave F, Gharbi D, Martin V, Vaucher L, Speiser DE, Romero P, Jichlinski P, Nardelli-Haefliger D.
    Clin Cancer Res; 2017 Feb 01; 23(3):717-725. PubMed ID: 27521445
    [Abstract] [Full Text] [Related]

  • 16. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ, Shen ZJ, Lu J, Jin XD, Chen J, Shi SF.
    Zhonghua Wai Ke Za Zhi; 2005 Nov 15; 43(22):1457-60. PubMed ID: 16318813
    [Abstract] [Full Text] [Related]

  • 17. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V, Pode D, Pikarsky E, Mandelboim O.
    J Urol; 2007 Dec 15; 178(6):2660-4. PubMed ID: 17945285
    [Abstract] [Full Text] [Related]

  • 18. [Urinary leukocytes as a new prognostic marker of therapeutic response and of adverse effects associated with the maintenance treatment with endovesical BCG, for the prophylaxis of superficial bladder tumors].
    Saint F, Irani J, Salomon L, Legrand P, Abbou CC, Chopin D.
    Prog Urol; 2001 Dec 15; 11(6):1242-50. PubMed ID: 11859659
    [Abstract] [Full Text] [Related]

  • 19. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM.
    J Urol; 2008 Oct 15; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [Abstract] [Full Text] [Related]

  • 20. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T, Alter A, Wiechno P.
    Urol Int; 2008 Oct 15; 80(1):74-9. PubMed ID: 18204238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.